Amanda Rae Maxwell
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Amanda Rae Maxwell has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
- Addis Yilma
Center for Tuberculosis Research, Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
1 shared publication - Alannah D. Taylor
W. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA
1 shared publication - Darla Quijada
Center for Tuberculosis Research, Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
1 shared publication Elisa M. Rouse Salcido
Center for Tuberculosis Research, Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
1 shared publication- Eric K. Hutchinson
Office of Laboratory Animal Medicine, University of Delaware, Newark, DE 19716, USA
1 shared publication - Eric Kenneth Hutchinson
Department of Molecular and Comparative Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland
1 shared publication
Latest Publications
- Open Access
- 1 March 2026
- Published by SPIE-Intl Soc Optical Eng in Journal of Biomedical Optics
- Vol. 31 (03) , 1-12
In vivo photoacoustic imaging of swine ureters injected with methylene blue
SignificanceUreteral injuries represent a major concern during a range of surgical procedures, due to the proximity of the ureter to target surgical structures. Intraoperative identification of the ureter is critical to prevent this accidental damage.AimWe demonstrate the first known in vivo photoacoustic imaging of the ureter in swine following intravenous administration of FDA-approved methylene blue, enabled by a software-hardware integration that has not been previously reported in the literature.ApproachPhotoacoustic channel data from the ureters of two swine were acquired using a Vevo F2 ultrasound system and an Opotek Phocus Mobile laser. Images were beamformed using a delay-and-sum algorithm. Photoacoustic image quality was evaluated using contrast, signal-to-noise ratio (SNR), and generalized contrast-to-noise ratio (gCNR) metrics, measured 10 to 80 min after methylene blue injection.ResultsAcross the 10- to 80-min imaging window, median contrast (3.46–11.43 dB), SNR (2.84–6.99), and gCNR (0.27–0.64) confirmed sustained ureter visibility with methylene blue. Maximum image quality was observed 20- to 30-min after methylene blue injection, with significantly higher contrast, SNR, and gCNR values compared with earlier or later time points (p<0.05).ConclusionsIn vivo results demonstrate that methylene-blue-enhanced photoacoustic imaging can visualize the ureter over a time duration that is consistent with the length of surgical procedures, providing initial feasibility for real-time photoacoustic-guided surgery applications.
- 1 March 2026
- Published by SPIE-Intl Soc Optical Eng in Journal of Biomedical Optics
- Vol. 31 (03) , 1-12
Open AccessIn vivo photoacoustic imaging of swine ureters injected with methylene blue
SignificanceUreteral injuries represent a major concern during a range of surgical procedures, due to the proximity of the ureter to target surgical structures. Intraoperative identification of the ureter is critical to prevent this accidental damage.AimWe demonstrate the first known in vivo photoacoustic imaging of the ureter in swine following intravenous administration of FDA-approved methylene blue, enabled by a software-hardware integration that has not been previously reported in the literature.ApproachPhotoacoustic channel data from the ureters of two swine were acquired using a Vevo F2 ultrasound system and an Opotek Phocus Mobile laser. Images were beamformed using a delay-and-sum algorithm. Photoacoustic image quality was evaluated using contrast, signal-to-noise ratio (SNR), and generalized contrast-to-noise ratio (gCNR) metrics, measured 10 to 80 min after methylene blue injection.ResultsAcross the 10- to 80-min imaging window, median contrast (3.46–11.43 dB), SNR (2.84–6.99), and gCNR (0.27–0.64) confirmed sustained ureter visibility with methylene blue. Maximum image quality was observed 20- to 30-min after methylene blue injection, with significantly higher contrast, SNR, and gCNR values compared with earlier or later time points (p<0.05).ConclusionsIn vivo results demonstrate that methylene-blue-enhanced photoacoustic imaging can visualize the ureter over a time duration that is consistent with the length of surgical procedures, providing initial feasibility for real-time photoacoustic-guided surgery applications.
- Open Access
- 3 February 2026
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136 (7)
Immunotherapy targeting drug-tolerant Mycobacterium tuberculosis persisters accelerates tuberculosis cure in preclinical models
Mycobacterium tuberculosis remains a global health crisis, ranking among the deadliest infectious diseases worldwide. In response to the WHO’s call for therapeutic vaccines to complement antibiotic regimens and reduce tuberculosis (TB) treatment duration, we developed an intranasal DNA vaccine fusing the M. tuberculosis stringent response gene relMtb with the gene encoding the DC-targeting chemokine Mip3a (also known as CCL20 ). Administered alongside the first-line regimen, this vaccine accelerated a stable cure in immunocompetent murine TB models, reducing lung inflammation and eliciting robust and sustained RelMtb-stimulated T cell responses systemically and locally. The Mip3a/relMtb vaccine enhanced DC recruitment, activation, and spatial coordination with T cells, suggesting improved innate-adaptive immune synergy. Notably, it augmented the efficacy of a novel drug-resistant TB regimen as well. Critically, the vaccine induced analogous antigen-stimulated T cell immunity in nonhuman primates, the gold standard for preclinical TB vaccine evaluation, with responses detected in blood and bronchoalveolar lavage mirroring those observed in the murine models. These findings underscore the potential of this strategy to advance therapeutic TB vaccine development targeting M. tuberculosis persisters while providing a framework to define correlates of vaccine-mediated protection.
- 3 February 2026
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136 (7)
Open AccessImmunotherapy targeting drug-tolerant Mycobacterium tuberculosis persisters accelerates tuberculosis cure in preclinical models
Mycobacterium tuberculosis remains a global health crisis, ranking among the deadliest infectious diseases worldwide. In response to the WHO’s call for therapeutic vaccines to complement antibiotic regimens and reduce tuberculosis (TB) treatment duration, we developed an intranasal DNA vaccine fusing the M. tuberculosis stringent response gene relMtb with the gene encoding the DC-targeting chemokine Mip3a (also known as CCL20 ). Administered alongside the first-line regimen, this vaccine accelerated a stable cure in immunocompetent murine TB models, reducing lung inflammation and eliciting robust and sustained RelMtb-stimulated T cell responses systemically and locally. The Mip3a/relMtb vaccine enhanced DC recruitment, activation, and spatial coordination with T cells, suggesting improved innate-adaptive immune synergy. Notably, it augmented the efficacy of a novel drug-resistant TB regimen as well. Critically, the vaccine induced analogous antigen-stimulated T cell immunity in nonhuman primates, the gold standard for preclinical TB vaccine evaluation, with responses detected in blood and bronchoalveolar lavage mirroring those observed in the murine models. These findings underscore the potential of this strategy to advance therapeutic TB vaccine development targeting M. tuberculosis persisters while providing a framework to define correlates of vaccine-mediated protection.
- Open Access
- 12 November 2024
- Published by MDPI AG in Veterinary Sciences
- Vol. 11 (11) , 560
Collaborating for the Successful Retirement and End-of-Life Care of Non-Human Primates in Biomedical Research
Research facilities have established animal adoption programs for laboratory animals. However, adoption to private owners is not an option for non-human primates (NHPs), so their post-research life presents a unique challenge. Here, we describe a collaborative effort between laboratory animal veterinarians and behavioral management staff in retiring NHPs in place to ensure their quality of life after the completion of research projects. The success of our retirement program hinges on our collaborative efforts to manage clinical diseases such as arthritis, amyloidosis, and diarrhea; to surgically ex-plant previous research hardware; and to evaluate the animals’ behavior and temperament to ensure each individual is placed in a new group or living situation in which they are likely to be successful and to have good welfare. Implementation of a quality-of-life assessment tool for all retired animals allows all staff involved in the animals’ care to proactively and periodically assess the quality of life of these animals. The successful retirement of NHPs living in social groups is rewarding for all personnel and promotes a culture of caring. Research animal retirement is an important way for us to give back and honor the contributions these animals have made to advancing medicine.
- 12 November 2024
- Published by MDPI AG in Veterinary Sciences
- Vol. 11 (11) , 560
Open AccessCollaborating for the Successful Retirement and End-of-Life Care of Non-Human Primates in Biomedical Research
Research facilities have established animal adoption programs for laboratory animals. However, adoption to private owners is not an option for non-human primates (NHPs), so their post-research life presents a unique challenge. Here, we describe a collaborative effort between laboratory animal veterinarians and behavioral management staff in retiring NHPs in place to ensure their quality of life after the completion of research projects. The success of our retirement program hinges on our collaborative efforts to manage clinical diseases such as arthritis, amyloidosis, and diarrhea; to surgically ex-plant previous research hardware; and to evaluate the animals’ behavior and temperament to ensure each individual is placed in a new group or living situation in which they are likely to be successful and to have good welfare. Implementation of a quality-of-life assessment tool for all retired animals allows all staff involved in the animals’ care to proactively and periodically assess the quality of life of these animals. The successful retirement of NHPs living in social groups is rewarding for all personnel and promotes a culture of caring. Research animal retirement is an important way for us to give back and honor the contributions these animals have made to advancing medicine.
- Open Access
- 31 August 2022
- Published by Wiley in Journal of Medical Primatology
- Vol. 51 (6) , 374-380
A comparison of different antibiotic regimens for the treatment of naturally acquired shigellosis in rhesus and pigtailed macaques (Macaca mulatta and nemestrina)
Background: Shigella spp. are common enteric pathogens in captive non‐human primates. Treatment of symptomatic infections involves supportive care and antibiotic therapy, typically with an empirical choice of antibiotic.Methods: Twenty‐four clinically ill, Shigella PCR‐positive animals were randomly assigned to one of four treatment groups: single‐dose ceftiofur crystalline free acid (CCFA), single‐dose azithromycin gavage, a 5‐day tapering azithromycin dose, or 7‐day course of enrofloxacin. We hypothesized that all antimicrobial therapies would have similar efficacy.Results: Animals in all groups cleared Shigella, based on fecal PCR, and had resolution of clinical signs 2 weeks after treatment. Eight out of nine clinically ill and PCR‐positive animals tested negative by fecal culture.Conclusions: Single‐dose CCFA, single‐dose azithromycin, and a 5‐day tapering course of azithromycin all performed as well as a 7‐day course of enrofloxacin in eliminating Shigella infection. Fecal PCR may be a better diagnostic than culture for Shigella.
- 31 August 2022
- Published by Wiley in Journal of Medical Primatology
- Vol. 51 (6) , 374-380
Open AccessA comparison of different antibiotic regimens for the treatment of naturally acquired shigellosis in rhesus and pigtailed macaques (Macaca mulatta and nemestrina)
Background: Shigella spp. are common enteric pathogens in captive non‐human primates. Treatment of symptomatic infections involves supportive care and antibiotic therapy, typically with an empirical choice of antibiotic.Methods: Twenty‐four clinically ill, Shigella PCR‐positive animals were randomly assigned to one of four treatment groups: single‐dose ceftiofur crystalline free acid (CCFA), single‐dose azithromycin gavage, a 5‐day tapering azithromycin dose, or 7‐day course of enrofloxacin. We hypothesized that all antimicrobial therapies would have similar efficacy.Results: Animals in all groups cleared Shigella, based on fecal PCR, and had resolution of clinical signs 2 weeks after treatment. Eight out of nine clinically ill and PCR‐positive animals tested negative by fecal culture.Conclusions: Single‐dose CCFA, single‐dose azithromycin, and a 5‐day tapering course of azithromycin all performed as well as a 7‐day course of enrofloxacin in eliminating Shigella infection. Fecal PCR may be a better diagnostic than culture for Shigella.